Safety & evidence

Fake and contaminated
peptides

The best-documented risk with unregulated peptide products is not the molecule on the label. It is that the vial does not contain what the label says.

Short answerSafety & evidence · 7 min read · Updated 17 Nov 2026

The best-documented risk with unregulated peptide products is a vial that does not match its label: the wrong substance, the wrong amount, low purity, toxic impurities or endotoxin. Regulators in Australia, the UK and the US, and peer-reviewed laboratory analyses, have recorded each of these. A full lab report can catch most of them for one batch.

Key takeaways

  • In September 2026 Australia's TGA reported a product sold as retatrutide that contained no retatrutide and about eight times the semaglutide level of the semaglutide products it had assessed.
  • Peer-reviewed analyses of peptide products sold online have found substituted contents, amounts far from the label, purity as low as 5%, arsenic, lead and endotoxin.
  • Each failure needs its own test: identity by mass spectrometry, purity by HPLC, quantity by assay, and separate endotoxin and sterility tests.
  • Seizures and case reports show that these failures happen. They cannot tell you how often.

01Five ways a vial can differ from its label

A label is a claim. A lab test is a measurement. Every failure below has been documented by a regulator or in a peer-reviewed analysis, and each one is caught by a different test.

FailureWhat it meansA documented exampleThe test that catches it
Wrong identityThe vial holds a different substance, a second substance, or none of the named one.TGA, 2026: a product sold as retatrutide contained no retatrutide and undeclared semaglutide. Reichel et al., 2019: only 9 of 17 black-market products labelled follistatin contained it; some of the others held different growth-promoting peptides.Mass spectrometry: observed mass against the expected mass. See mass spectrometry explained.
Wrong amountMore or less peptide than the label states.Ashraf et al., 2024: three semaglutide vials from illegal online pharmacies held 29–39% more semaglutide than labelled. Janvier et al., 2018: high variation in the amount per unit.A quantitative assay and net peptide content. See purity explained.
Low purityMuch of the material is related peptides: shortened, extended or modified sequences.Janvier et al., 2018: purity between 5% and 75% for the cysteine-containing peptides among ten falsified peptide drugs.HPLC, with the chromatogram shown. See HPLC explained.
Toxic non-peptide impuritiesMetals, solvents or other chemicals left from manufacture.Janvier et al., 2018: inorganic arsenic and lead; several samples reached up to ten times the international (ICH) limit for drugs given by injection.Elemental analysis and residual-solvent testing, which most peptide reports do not include.
Endotoxin or microbesBacterial material, or live organisms, in a product meant to be sterile.Ashraf et al., 2024: no live microorganisms, but endotoxin in all three vials. FDA, 2026: at least 30 patients with fever, chills and signs of shock after IV glutathione compounded from a dietary-supplement-grade ingredient; FDA said the symptoms were consistent with excessive endotoxin, and two pharmacies recalled products over elevated endotoxin levels.A bacterial endotoxin test and a sterility test, run separately. See endotoxin and sterility testing.

Glutathione is a three-amino-acid peptide. The 2026 cases came from compounding pharmacies, not the research market, which is why they matter here: the ingredient was a dietary-supplement grade that FDA says should not be used to make these products, and only a test would have shown the endotoxin.

02Documented cases, by date

Regulator notices and peer-reviewed analyses only. Each item is dated to its primary document.

1
2018 · Belgium

The Belgian public health institute analysed the ten falsified peptide drugs it most often encountered, sourced from three suspected illegal internet pharmacies. It found wide variation in amount, low purity, and arsenic and lead (Janvier et al., Talanta).

2
2018–2019 · Anti-doping labs

Doping-control laboratories found glycine-extended versions of GHRP-2, GHRP-6 and ipamorelin in black-market products (Krug et al., 2018), and follistatin products where 8 of 17 did not contain follistatin (Reichel et al., 2019).

3
2024 · Online semaglutide

Researchers sourced semaglutide from six illegal online pharmacies; three vials arrived. All three held more than the label stated, all three contained endotoxin, and measured purity was 7.7–14.4% against the 99% printed on the labels; the authors found no peptide-like impurities (Ashraf et al., J Med Internet Res). Semaglutide is a prescription medicine; these vials were not the approved product.

4
19 June 2026 · Victoria, Australia

The state health department reported six cases of acute liver injury since January 2026 linked to products labelled Retatrutide, Reta, R-10 or R-20, possibly from a contaminant. The contaminant was not named; investigation was under way.

5
July 2026 · US FDA

In its briefing on BPC-157 for the Pharmacy Compounding Advisory Committee, FDA staff reported that a literature search found most certificates of analysis for BPC-157 contained only a purity result.

6
14 September 2026 · Australia, TGA

The TGA said laboratory testing of a product sold as retatrutide found no retatrutide, but undeclared semaglutide at about eight times the level in the semaglutide products it had assessed. The person was hospitalised with a torn oesophagus after uncontrollable vomiting (reported by ABC News). Retatrutide is investigational and not approved anywhere.

7
15 October 2026 · UK, MHRA

The MHRA and West Midlands Police seized over 12,000 fake retatrutide and tirzepatide pens. The MHRA said the products had not been assessed for safety, quality or effectiveness, and that there was no guarantee of what they contained or whether they had been contaminated with harmful substances.

8
27 October 2026 · Victoria, Australia

The Chief Health Officer reported 13 cases of anaphylaxis linked to unapproved peptides since July 2025, and said the substance, concentration and possible contaminants in these products are unknown.

03What a full lab report catches, and what it can't

A certificate of analysis is only as complete as the tests it lists. A purity percentage on its own answers one question out of five.

  • Identity, if mass spectrometry is reported with an observed and an expected mass.
  • Purity, if HPLC is reported with the chromatogram and the method.
  • Quantity, if net peptide content or an assay against a reference is reported.
  • Endotoxin and sterility, if each test is listed with its method and result.
  • Metals and solvents, only if those tests were run. Most peptide reports do not include them.
  • Whether your vial came from the tested lot, unless the batch number matches.
  • What happened to the vial in transit or storage after testing.
  • Whether the substance is safe or effective in people. Quality and safety are different questions.

To check a report line by line, use how to read a COA. To judge who ran the test, see what “third-party tested” means and independent peptide labs.

04What we don't know

  • How common these failures are. Seizures, case reports and small samples (three vials in the 2024 study) show that failures happen. None of them gives a rate across the market.
  • The quality of research-labelled BPC-157, TB-500 or GHK-Cu sold online. As of November 2026 we found no peer-reviewed independent survey of these products. Most published analyses concern GLP-1 drugs and doping substances.
  • The cause in several cases. The Victorian liver-injury alert suspected a contaminant without naming one. The anaphylaxis advisory did not attribute the cases to a specific substance or impurity.
  • What a clean report means for safety. A correctly identified, pure, endotoxin-tested vial of a compound with little human safety data still has little human safety data. That question is covered in are peptides safe and peptide side effects.

Suspected reaction to any product? Seek medical care first, then report it: FDA MedWatch in the US, the MHRA Yellow Card scheme in the UK, the TGA in Australia. For anything about your health, a doctor who knows you is the right call.

This content is educational. It is not medical advice and does not describe use in humans. 6AM Wellness products are sold for research use only and are not for human consumption. If you have a health condition, consult a licensed clinician who knows you.

RefSources

  1. Carbonell R. Patient suffers torn oesophagus after using unapproved peptide, prompting fresh warnings. ABC News (Australia), 14 September 2026. www.abc.net.au/news/2026-09-14/tga-peptide-warning-retatruti…
  2. Department of Health, Victoria. Toxicity linked to unapproved peptide product labelled ‘Retatrutide’. Health alert, 19 June 2026. www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapp…
  3. Department of Health, Victoria. Anaphylaxis notifications linked to unapproved peptides. Health advisory 261027, 27 October 2026. www.health.vic.gov.au/health-advisories/anaphylaxis-notifica…
  4. Medicines and Healthcare products Regulatory Agency. Counterfeit weight loss pens worth £2 million seized by MHRA and West Mids Police. GOV.UK press release, 15 October 2026. www.gov.uk/government/news/counterfeit-weight-loss-pens-wort…
  5. US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026. www.fda.gov/media/193343/download
  6. US Food and Drug Administration. FDA reminds compounders not to use dietary supplement-grade glutathione in injectables. FDA notice, 27 August 2026. www.fda.gov/drugs/human-drug-compounding/fda-reminds-compoun…
  7. Ashraf AR, Mackey TK, Vida RG, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res, 2024;26:e65440. PMID 39509151. pubmed.ncbi.nlm.nih.gov/39509151/
  8. Janvier S, Cheyns K, Canfyn M, et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta, 2018;188:795–807. PMID 30029448. pubmed.ncbi.nlm.nih.gov/30029448/
  9. Reichel C, Gmeiner G, Thevis M. Detection of black market follistatin 344. Drug Test Anal, 2019;11(11–12):1675–1697. PMID 31758732. pubmed.ncbi.nlm.nih.gov/31758732/
  10. Krug O, Thomas A, Malerød-Fjeld H, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res, 2018;41:1–6. PMID 29864719. pubmed.ncbi.nlm.nih.gov/29864719/
  11. Therapeutic Goods Administration. TGA tests counterfeit retatrutide product following serious adverse event report. TGA safety alert, 14 September 2026. www.tga.gov.au/safety/safety-monitoring-and-information/safe…

Plain-English summary of public sources, not legal or medical advice. Last checked 17 Nov 2026.

Questions

Can you tell a fake peptide by its colour, smell or how it dissolves?

No. Appearance, smell and solubility are not analytical tests. Only laboratory tests of identity, amount and purity can say what is in a vial.

Does a 99% purity figure mean a vial is clean?

No. HPLC purity measures how much of the peptide material is the right sequence. It does not confirm identity, quantity, endotoxin or sterility, and it says nothing about effects in people.

Is endotoxin the same as bacterial contamination?

Not quite. Endotoxin is material from bacteria and can be present when no live bacteria are: the 2024 semaglutide study found endotoxin in vials that grew no microorganisms. That is why endotoxin and sterility are separate tests.

Are fake peptides only a problem with weight-loss drugs?

Most documented cases involve GLP-1 drugs such as semaglutide, tirzepatide and retatrutide. Anti-doping laboratories have also found substituted or unexpected substances among growth-hormone-releasing peptides and follistatin products.

Where do I report a suspected reaction?

FDA MedWatch in the US, the MHRA Yellow Card scheme in the UK, and the TGA in Australia. Seek medical care first if symptoms are serious.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page
Every batch has a public lab report. Look it up by the batch number on the vial. Batch COA lookup